Eisai (company)

{{Short description|Japanese pharmaceutical company}} {{Multiple issues| {{More citations needed|date=January 2018}} {{Expand Japanese|エーザイ|date=March 2020}} }} {{Use mdy dates|date=February 2015}}

{{Infobox company | name = Eisai Co., Ltd. | native_name = エーザイ株式会社 | native_name_lang = ja | romanized_name = Ēzai kabushiki gaisha | logo = Eisai logo.svg | logo_size = 200px | image = Eisai Head Office.jpg | type = Public KK | traded_as = {{TYO|4523}} TOPIX Large 70 Component TOPIX 100 Component Nikkei 225 Component | founder = Toyoji Naito | foundation = {{Start date and age|1941|12|06}} | location = 4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan | key_people = Haruo Naito (President and CEO) | industry = Pharmaceuticals | products = {{unbulleted list|Lecanemab | Lenvema| Halaven| Aricept|Pariet|Banzel|Zonegran|Fycompa|Zebinix}} | revenue = {{Increase}} ¥ 741.8 billion (2023)<ref name=EisaiRep23 /> | operating_income = {{Increase}} ¥ 53.4 billion (2023)<ref name=EisaiRep23 /> | net_income = {{Increase}} ¥ 43.8 billion (2023)<ref name=EisaiRep23 /> | assets = {{Increase}} ¥ 743.9 billion (2023)<ref name=EisaiRep23 /> | equity = {{Increase}} ¥ 430.2 billion (2023)<ref name=EisaiRep23 /> | owner = The Master Trust Bank of Japan (11.78%) Japan Trustee Services Bank (10.99%) Nippon Life (4.29%)<ref name=EisaiRep19 /> | num_employees = {{Increase}} 10,000 (2023)<ref name=EisaiRep23 /> | homepage = {{Official website|http://www.eisai.com}} | footnotes = <ref name=EisaiRep19>{{cite web|title=Eisai Financial Summary 2019|url=http://fs.magicalir.net/tdnet/2019/4523/20190513422653.pdf|access-date=21 December 2020|archive-date=July 9, 2022|archive-url=https://web.archive.org/web/20220709153435/http://fs.magicalir.net/tdnet/2019/4523/20190513422653.pdf|url-status=dead}}</ref> <ref name=EisaiRep23>{{cite web|title=Eisai Financial Summary 2023|url=https://www.eisai.com/ir/library/settlement/pdf/e2024Q4_51.pdf|access-date=2 July 2024}}</ref> }}

{{nihongo|'''Eisai Co., Ltd.'''|エーザイ株式会社|Ēzai Kabushiki-gaisha|lead=yes}} is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. '''Eisai''' is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.<ref>{{cite web |url=http://indexes.nikkei.co.jp/en/nkave/index/component?idx=nk225#09 |title=Components:Nikkei Stock Average |publisher=Nihon Keizai Shimbun |access-date=February 9, 2015}}</ref>

==History == Nihon Eisai Co. Ltd. was established in 1941.<ref>{{cite web|url=https://www.eisai.com/company/profile/history/index.html|title = Eisai: The First 80 Years | Eisai Co., Ltd}}</ref> In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.<ref>{{cite encyclopedia |first=Claudia |last=Winograd |editor-last=Colditz |editor-first=Graham A. |title=Eisai (Japan) |encyclopedia=Encyclopedia of Cancer and Society |date=October 16, 2007 |publisher=SAGE Publications |url=http://www.sageknowledge.org/view/cancer/n204.xml |doi=10.4135/9781412953979 |isbn=9781412949897 |access-date=February 9, 2015 |archive-date=February 9, 2015 |archive-url=https://web.archive.org/web/20150209165035/http://www.sageknowledge.org/view/cancer/n204.xml |url-status=dead |url-access=subscription }}</ref> The American subsidiary of the company, Eisai Inc., was established in 1995.<ref>{{cite press release |url=http://www.businesswire.com/news/home/20100618005322/en/Lonnel-Coats-Appointed-President-Chief-Executive-Officer#.VNik5S5vW4A |title=Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc. |publisher=Businesswire |access-date=February 9, 2015}}</ref>

On November 25, 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer.<ref>{{cite web|url=https://www.newspapers.com/image/102245190/?terms=Aricept |title=27 Nov 1996, Page 11 - The Cincinnati Enquirer at |publisher=Newspapers.com |date=1996-11-27 |accessdate=2022-06-05}}</ref>

Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.

In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals.<ref>{{cite web|url=https://www.biospace.com/article/eisai-inc-buys-4-cancer-drugs-from-ligand-pharmaceuticals-inc-for-205-million-/|title=Eisai Inc. Buys 4 Cancer Drugs From Ligand Pharmaceuticals Inc. For $205 Million|website=BioSpace|language=en-US|access-date=2020-02-21|archive-date=April 17, 2021|archive-url=https://web.archive.org/web/20210417033704/https://www.biospace.com/article/eisai-inc-buys-4-cancer-drugs-from-ligand-pharmaceuticals-inc-for-205-million-/|url-status=dead}}</ref>

In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases.

In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for US$3.9 billion.<ref>{{Cite news|url=https://www.reuters.com/article/us-mgi-pharma-eisai-idUSTKV00291420071210|title=Japan's Eisai to buy MGI Pharma for $3.9 bln|date=2007-12-10|work=Reuters|access-date=2019-11-20|language=en}}</ref> This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.

In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel (rufinamide).<ref>{{cite news |url=http://www.prnewswire.com/news-releases/nord-to-honor-rare-disease-pioneers-61818702.html |archive-url=https://web.archive.org/web/20150209123421/http://www.prnewswire.com/news-releases/nord-to-honor-rare-disease-pioneers-61818702.html |archive-date=February 9, 2015 |title=NORD to Honor Rare Disease Pioneers |publisher=PR Newswire |date=May 11, 2009 |access-date=February 9, 2015}}</ref>

In 2010, Eisai's Halaven (eribulin mesylate) was approved for advanced or metastatic breast cancer in the United States, with approvals in the European Union (EU), Japan and Canada following in 2011.

In June 2023, the company suffered from a ransomware attack, causing a shutdown of some of its logistical systems.<ref>{{cite web | url=https://www.securityweek.com/pharmaceutical-giant-eisai-takes-systems-offline-following-ransomware-attack/ | title=Pharmaceutical Giant Eisai Takes Systems Offline Following Ransomware Attack | date=June 8, 2023 }}</ref>

Lecanemab, branded as "Leqembi" was approved by the U.S. Food and Drug Administration (FDA) in January 2023 under an Accelerated Approval pathway.<ref>{{Cite web |last=Commissioner |first=Office of the |date=2023-01-06 |title=FDA Grants Accelerated Approval for Alzheimer's Disease Treatment |url=https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment |archive-url=https://web.archive.org/web/20230106192500/https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment |url-status=dead |archive-date=January 6, 2023 |access-date=2024-07-02 |website=FDA |language=en}}</ref> The approval was converted into a traditional approval in July 2023.<ref>{{Cite web |last=Commissioner |first=Office of the |date=2023-07-07 |title=FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval |url=https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval |access-date=2024-07-02 |website=FDA |language=en}}</ref>

==Locations== Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary, Eisai Inc., is headquartered in Nutley, New Jersey. Eisai Inc. is led by Ivan Cheung as CEO.<ref>{{Cite news |last=Bell |first=Jacob |date=February 6, 2023 |title=Eisai gives first glimpse into Alzheimer's drug launch |work=BiopharmaDive |publisher=Informa |location=Washington, D.C. |url=https://www.biopharmadive.com/news/eisai-alzheimers-leqembi-launch-earnings/642067/ |access-date=February 11, 2023 |archive-url=https://web.archive.org/web/20230206223238/https://www.biopharmadive.com/news/eisai-alzheimers-leqembi-launch-earnings/642067/ |archive-date=February 6, 2023}}</ref> Eisai maintains medical research headquarters in Nutley as well as at locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based.<ref name="carroll2016">{{Cite news|url=https://endpts.com/eisai-launches-research-division-in-massachusetts-aimed-at-alzheimers-io-and-autoimmune-diseases/|title=Eisai launches biotech division in Massachusetts aimed at Alzheimer's, I/O and autoimmune diseases|last=Carroll|first=John|date=15 September 2016|work=Endpoint News|access-date=4 November 2016}}</ref><ref name="genengnews2016">{{Cite news|title=Eisai Launches Facility to Advance Precision Medicine|last=|date=15 October 2016|work=Genetic Engineering & Biotechnology News|department=News: Industry Watch|page=8|type=Paper}}</ref>

The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.

==Products== Some of the key products that Eisai produces or markets with partners include:

*Aciphex/Pariet (rabeprazole) - Gastroesophageal reflux disease *Actonel (risedronic acid) - Osteoporosis (Japan) *Aloxi (palonosetron) - Chemotherapy-induced nausea and vomiting *Aricept (donepezil) - Mild to moderate dementia for Alzheimer's Disease patients *Banzel/Inovelon (rufinamide) - Seizures related to Lennox-Gastaut Syndrome *Belviq (lorcaserin) - Obesity *Dayvigo (lemborexant) - Insomnia *Fragmin (dalteparin) - Deep vein thrombosis and pulmonary embolism *Fycompa (perampanel) - Partial-onset seizures *Gliadel Wafer (carmustine) - Treatment for Brain Tumors *Halaven (eribulin) - Metastatic breast cancer *Iomeron (iomeprol) - Non-ionic contrast medium *Lenvima (lenvatinib) - Thyroid Cancer or Kidney Cancer *Leqembi (lecanemab) - Alzheimer's disease *Methylcobal (methylcobalamin) - Peripheral neuropathy *Myonal (eperisone) - Muscle relaxant *Selbex (teprenone) - Gastric ulcers and gastritis *Zonegran (zonisamide) - Partial-onset seizures ===Aricept=== Aricept accounted for 40% of Eisai's revenue as of March 2010.<ref name=bb20110425>{{cite news |title=Eisai Aricept Patch for Alzheimer's Isn't Ready for Approval |author=Kanoko Matsuyama |agency=Bloomberg L.P. |date=April 25, 2011 |access-date=April 25, 2011 |url=https://www.bloomberg.com/news/2011-04-25/eisai-says-fda-indicates-aricept-nda-not-ready-for-approval.html }}</ref> The main competitor to Aricept is a generic formulation from Ranbaxy Labs.<ref name=bb20110425/> Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.<ref name=bb20110425/>

==See also== {{Portal bar|Japan|Medicine|Companies}} * Biotech and pharmaceutical companies in the New York metropolitan area

==References== {{Reflist}}

==External links== * {{Official website}}

Category:Life sciences industry Category:Pharmaceutical companies based in Tokyo Category:Companies listed on the Tokyo Stock Exchange Category:Companies in the Nikkei 225 Category:Pharmaceutical companies established in 1941 Category:Japanese companies established in 1941 Category:Japanese brands Category:Pharmaceutical companies based in New Jersey